- Current report filing (8-K)
August 22 2011 - 9:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported)
August 22, 2011
Cephalon, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
0-19119
|
|
23-2484489
|
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
41 Moores Road
|
|
|
|
Frazer, Pennsylvania
|
|
19355
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
(610) 344-0200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
Other Information
.
On August 22, 2011, Cephalon, Inc. (the “Company”) issued a press release announcing that the Company has given notice of an anticipated fundamental change to holders of the Company’s 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 in respect of the previously announced merger of the Company with a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., which is expected to become effective in October 2011. The Company hereby incorporates by reference the press release dated August 22, 2011, attached hereto as Exhibit 99.1 and made a part of this Item 8.01.
Item 9.01
Financial Statements and Exhibits
.
(d)
Exhibits
.
|
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
|
|
99.1
|
|
Press Release of Cephalon, Inc. dated August 22, 2011
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CEPHALON, INC.
|
|
|
|
|
|
|
|
|
Date: August 22, 2011
|
By:
|
/s/ Gerald J. Pappert
|
|
|
|
Gerald J. Pappert
|
|
|
|
Executive Vice President, General Counsel and Secretary
|
3
EXHIBIT INDEX
|
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
|
|
99.1
|
|
Press Release of Cephalon, Inc. dated August 22, 2011
|
4
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Dec 2023 to Dec 2024
